Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Vasculitis
When advising patients on starting Avacopan for Granulomatosis with polyangiitis, what side effects do you tell patients are commonly seen in clinical practice?
Related Questions
How would you manage active psoriasis and psoriatic arthritis in patient on Rituximab and prednisone for MPO positive vasculitis?
What is your approach to management of pulmonary fibrosis in patients with a history of microscopic polyangiitis who do not have other active organ involvement?
How do you approach the workup and management of isolated orbital inflammatory pseudotumor/granuloma?
How would you approach the work up of a patient with nasal septal perforation, a negative infectious workup, and negative ANCA titers?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
How do you approach the workup of clinically diagnosed cutaneous vasculitis in healthy young individuals without systemic symptoms?
How would you approach a patient with EGPA, with main manifestations of asthma, nasal polyposis, and mononeuritis multiplex, who has clinically responded to rituximab, yet has persistently high eosinophilia (>40%)?
How would you approach management of a patient with a medium-to-large vessel vasculitis who developed perforation of the stomach and colon on steroids and cyclophosphamide?
Do you send anti-human neutrophil elastase antibodies when you suspect levamisole-induced ANCA vasculitis?
Are you aware of drug induced-ANCA vasculitis associated with new wt loss medications (ex tirzepatide or semaglutide?
